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Abstract
Meneses, M.L.; Martin, P.L.; Manzuc, P.; Arauz, M.S.; Pardo, A.G.: Staphylococcus 
sp, antimicrobial treatment and resistance in canine superficial bacterial pyoderma. Rev. 
vet. 29: 2, 88-92, 2018. In Buenos Aires, Argentina, few studies are available regarding the 
frequency of the antimicrobial treatment for canine pyoderma and the level of antimicrobial 
resistance of Staphylococcus sp. The main objectives of this study were to analyze the an-
timicrobial resistance of Staphylococcus sp and the frequency of antimicrobial treatment of 
canines with pyoderma and their relapses. A total of 39 canines with clinical diagnosis of 
pyoderma from private veterinary clinics in Buenos Aires area, were analyzed. Skin lesions 
swabs for both bacterial culture and mass spectrometry analysis were collected at the time of 
active pyoderma. Additionally, breed, sex, pyoderma classification, antimicrobial treatment 
and relapses of disease were recorded. Seventy-six percent of the studied animals received 
oral cephalexin after the clinical checkup, and within this percentage 31.6% also received 
other types of antimicrobial agents due to relapses. The remaining 24% had only antimi-
crobial treatment with lincomycin, minocycline and/or doxycycline. In sixty percent of the 
animals, pyoderma was related to allergy, which in turn was in concordance with relapses 
and was similar to the percentage of methicillin resistance (51%) of the different isolates 
of Staphylococcus sp. Eighty percent of the methicillin resistances were previously treated 
with cephalexin. Surprisingly, the highest percentages of resistance were to erythromycin, 
clindamycin (demonstrating constitutive MLSB phenotype), and sulfatrimethoprim.
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Resumen
Meneses, M.L.; Martin, P.L.; Manzuc, P.; Arauz, M.S.; Pardo, A.G.: Staphylococcus 
sp, tratamiento antimicrobiano y resistencia en pioderma bacteriana superficial canina. 
Rev. vet. 29: 2, 88-92, 2018. En la Provincia de Buenos Aires, Argentina, existen pocos es-
tudios sobre la frecuencia del tratamiento antimicrobiano en pioderma canina y el nivel de 
resistencia antimicrobiana de Staphylococcus sp. Los principales objetivos de este estudio 
fueron analizar la resistencia antimicrobiana de Staphylococcus sp, la frecuencia del trata-
miento antimicrobiano y sus recidivas en caninos con pioderma. Se analizaron 39 caninos 
con diagnóstico clínico de pioderma, procedentes de clínicas veterinarias privadas del área 
de Buenos Aires. Se recogieron, en el momento de la pioderma activa, hisopados de lesiones 
cutáneas para cultivo bacteriano y análisis por espectrometría de masas. Además, se registró 
raza, sexo, clasificación clínica de la pioderma, tratamiento antimicrobiano y recaídas de la 
enfermedad. El 76% de los animales estudiados recibieron cefalexina por vía oral después 
del examen clínico, y dentro de este porcentaje, el 31,6% también recibió otros tipos de 
agentes antimicrobianos debido a recaídas. El 24% restante recibió como tratamiento anti-
microbiano lincomicina, minociclina y/o doxiciclina. En el 60% de los animales estudiados, 
la pioderma diagnosticada tenía una causa alérgica, que a su vez coincidió con las recaídas 
y fue similar al porcentaje de resistencia a la meticilina (51%) de los diferentes aislamientos 
de Staphylococcus sp. El 80% de las resistencias a meticilina observadas se trataron previa-
mente con cefalexina. Inesperadamente, el mayor porcentaje de resistencia observada fue a 
eritromicina, clindamicina (demostrando fenotipo constitutivo MLSB) y sulfatrimetoprima.
Palabras clave: canino, Staphylococcus sp, pioderma, resistencia antimicrobiana.
89
INTRODUCTION
Superficial bacterial folliculitis or superficial pyo-
derma, is a bacterial infection confined to the superfi-
cial portion of the hair follicle 22 . It is commonly ac-
cepted that canine pyoderma is usually associated with 
underlying causes such as allergies or endocrinopa-
thies that either break down the epidermal barrier and/
or produce alterations in the immune system. Identifi-
cation and control of the underlying causes is critical 
for effective treatment and prevention of recurrence 12 . 
Staphylococcus pseudointermedius 24 (SPI), for-
merly Staphylococcus intermedius (SI), is considered 
the most frequently isolated bacterial pathogen in ca-
nine pyoderma 25 . Less commonly, dogs may also be 
colonized and infected by other Staphylococcus spe-
cies and other bacteria 22 . 
Recently, guidelines for antimicrobial therapy for 
canine superficial bacterial folliculitis were published, 
although these recommendations were for diagnosis 
and based mainly on clinical signs emphasizing the 
need for demonstration of cocci in lesional skin by cy-
tology as a powerful adjunctive diagnostic test 15 .
It is good practice to perform impression cytology 
as an in-clinic test while diagnosing skin infections. 
Hence, appropriate techniques have been described for 
both specimen collection and examination to optimize 
the value of this diagnostic procedure 15 .
Bacterial culture for canine pyoderma is never con-
traindicated and is, in fact, encouraged in patients with 
chronic or recurrent pyoderma due to the increased fre-
quency of isolation of antibiotic resistant staphylococci 
in veterinary medicine over the past decade 13 . 
At present, methicillin-resistant Staphylococcus 
aureus (MRSA) is one of nine bacterial pathogens of 
particular public health concern declared by the World 
Health Organization in its 2014 antimicrobial resistance 
surveillance report. This report describes resistance as 
a problem so serious that it jeopardizes the achieve-
ments of modern medicine. In the post-antibiotic era, 
where common infections and minor injuries can kill, 
far from being an apocalyptic fantasy, it is instead a 
very real possibility in the 21st century 30 . Likewise, 
this threat also applies to staphylococcal infections in 
veterinary medicine. 
The first signs of change in the veterinary sector 
were in the late 1990s with the emergence of clinical 
infections in companion animals, initially with MRSA 
and then with methicillin-resistant SPI (MRSP) 18 .
MRSP strains are characterized by the presence of 
the mecA gene that encodes for a low affinity penicillin 
binding protein (PBP2a); this altered protein confers 
resistance to all b-lactam antibiotics, including peni-
cillins, cephalosporins and carbepenems 16 . MRSP are 
frequently resistant to multiple classes of antibiotics, 
including fluoroquinolones, tetracyclines, macrolides 
and others 10 .
Such infections, mainly of dermal origin, led to an 
increase in the prevalence of MRSP, initially attract-
ing attention in the United States and soon after in Eu-
rope 17, 23 . This threat has been strongly reinforced by a 
recent report from China that almost 50% of S. pseud-
intermedius isolates from dogs were MRSP 19 .
At the moment there are few studies indicating 
the prevalence of this microorganism in our region. 
Therefore, the aims of our study were to evaluate this 
prevalence, to analyze the antimicrobial sensitivity and 
to consider the antimicrobial treatment applied and its 
evolution in canines with a diagnosis of pyoderma.
MATERIAL AND METHODS
Sampling. We analyzed 39 cases of canines with 
superficial bacterial pyoderma from private veterinary 
clinics in the Province of Buenos Aires, diagnosed by 
clinical symptomatology and with their respective cy-
tological confirmation. They were sampled from der-
mal lesions and tested for bacteriological identification 
and evaluation of antimicrobial susceptibility. At the 
same time, the implemented treatments and their clini-
cal evolution were followed up.
Isolates identification. The samples were analyzed 
at the Central Laboratory of the Veterinary Sciences 
School Hospital of the National University of La Plata, 
Argentina. The following biochemical tests were per-
formed: saline mannitol agar, catalase, coagulase, pyr 
(pyrrolidonyl-beta-naphthylamide) and acetoin. Subse-
quently, the samples were analyzed by mass spectrom-
etry at the Special Bacteriology Service of the National 
Institute of Infectious Diseases (Dr. Carlos G. Malbrán) 
in the autonomous city of Buenos Aires, Argentina.
Antimicrobial susceptibility. Isolates were evalu-
ated by the agar diffusion method according to the M2-
A11 standards described in the guidelines from CLSI 
(Clinical & Laboratory Standards Institute) and those 
described in CLSI Approved Standard Supplement Vet 
01-S2 6, 7 . We used oxacillin 1 μg, erythromycin 15 μg, 
clindamycin 2 μg, ciprofloxacin 5 μg, chloramphenicol 
30 μg, trimethoprim-sulfamethoxazole 25 μg, rifampi-
cin 5 μg, gentamicin 10 μg and minocycline 30 μg (Bri-
tania Laboratory, Buenos Aires, Argentina).
Statistical analysis. The frequency of each isolated 
Staphylococcus species and resistance to the antibiotics 
used were expressed as a percentage with a confidence 
interval of 95% 1 .
RESULTS
The Staphylococcus species identified by mass 
spectrometry (MALDI-TOF) were S. pseudointerme-
dius-S. intermedius group 72%, S. pseudointermedius 
15%, S. aureus 5% and S. haemolyticus, xylosus/suc-
cinus, Schleiferi 3% (Figure 1). 
It is important to note that the S. pseudointermedi-
us-S. intermedius and S. xylosus/succinus species were 
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not able to be confirmed by sequencing the dnaJ, tuf or 
rpoB genes as indicated by CLSI mM18A 5 since access 
to the proper equipment could not be acquired.
A high percentage of multidrug resistances were 
observed in antimicrobial susceptibility tests, showing 
in 10 samples susceptibility for only one or two antimi-
crobials. Figure 2, shows the percentage of antimicrobi-
al resistances for all isolates of staphylococcal species. 
Likewise, in Table 1 the frequency of the antimi-
crobial systemic treatment is observed. It should be 
noted that the animals with recurrences received sev-
eral different antimicrobial treatments.
Seventy-six percent of the animals studied received 
cefalexin or cefadroxil orally after the clinical visit, and 
among these, 32% received in addition other types of 
antimicrobials due to relapses. The remaining 24% re-
ceived lincomycin, minocycline and/or doxycycline as 
the sole antimicrobial treatment. In turn, 96% of the ani-
mals also received topical treatments with chlorhexidine 
baths. 
In Table 2 the frequency of breeds studied is 
showed with their respective diagnostics. In 64% of 
the studied animals, pyodermia was due to an aller-
gic cause. In turn, this percentage coincides with the 
relapses observed and is similar to the percentage of 
methicillin resistance (51%) of the different isolates of 
Staphylococcus.
Regarding the frequency discriminated by sex we 
found 22 females (56%) and 17 males (43%). It should 
be stressed that 80% of the methicillin-resistant ob-
served were previously treated with cephalexin and 
the remaining 20% had no previous treatment records. 
However, the highest percentage of resistance observed 
were to erythromycin, clindamycin and sulfatrim-
ethoprim.
DISCUSSION
As described in the epidemiological study of others 
authors, it was also observed in our study that canine 
pyoderma is more frequent in purebred dogs 26 . Ad-
ditionally, agrees the frequency of incidence discrimi-
nated by sex mentioned by others authors 2, 27.
 Staphylococcus intermedius was first described 
in pigeon, dog, mink and horse isolates 14 . For more 
than 30 years, S. intermedius was considered the most 
common causal pathogen in skin and soft tissue infec-
tions in dogs 20 . However, high levels of genotypic and 
phenotypic diversity have been observed by several 
researchers suggesting the existence of more than one 
species 14 .
Recent studies have shown that the isolates pheno-
typically identified as S. intermedius differ, in fact, in 
three different species specifically known as S. interme-
dius, S. pseudintermedius 11 and S. delphini, which are 
collectively referred to as the S. intermedius group 3 . 
S. delphini was isolated from purulent skin lesions 
in dolphins and has rarely been reported since 28 . The 
recently described S. pseudintermedius species, not S. 
Figure 1. Percentage of isolated Staphylococcus spe-
cies (n=39). 
Figure 2. Percentage (%) of antimicrobial resistance 
(n=39).
Table 1. Frequency of antimicrobial treatments.
antimicrobial treatment % Nº
cephalexin 51 20
cefadroxil / minocycline 5 2
cephalexin /lincomycin / minocycline 5 2
cephalexin / doxycycline 15 6
lincomycin 5 2
minocycline 8 3
doxycycline 11 4
Table 2. Frequency of canine breeds and their respec-
tive diagnoses.
canine breed % Nº diagnosis
french bulldog 8 3 SPDAR
beagle 5 2 “
boxer 5 2 “
cocker spaniel 5 2 “
crossbreed 13 5 SPWUPC
dogue de bordeaux 5 2 “
english bulldog 5 2 SPDAR
german shepher 8 3 “
labrador retriever 5 2 “
pitbull 13 5 “
schnauzer 5 2 “
shar pei 5 2 “
terrier 5 2 “
toy poodle 8 3 “
white swiss shepher 5 2 SPIC
SPDAR: superficial pyoderma due to allergic reaction; SP-
WUPC: superficial pyoderma with unknown primary cause; 
SPIC: superficial pyoderma in calluses. 
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intermedius, is the most common cause of cutaneous 
infections in canines 4 .
Proteomic mass spectrometry (MALDI-TOF MS 
or laser assisted array of ionization desorption) is a fast 
and highly accurate technique that has been introduced 
in human and animal diagnostic laboratories 4 . Data-
bases of mass spectra are initially classified by identifi-
cations based on 16S and 18S rDNA sequences 4 . 
Recently, MALDI-TOF MS has been applied for 
species differentiation within the SIG group 8 . The 
estimated sensitivity and specificity for S. pseudinter-
medius were 78 and 97%, respectively, indicating that 
this approach might be useful for rapid and accurate 
identification at the species level 8 .
S. pseudintermedius is the major cause of canine 
pyoderma 22 . Coinciding with other authors 4, 21 , our 
study observed a high frequency of S. pseudointerme-
dius as causal to canine pyoderma. Bacteria can cause 
infection following the effects of local trauma, scratch-
ing, lack of grooming, seborrhea, parasitic infestation, 
hormonal factors, local irritants, or allergens 21 . 
In our case, 60% of the animals studied had an al-
lergic reaction as the primary cause. As expected, these 
animals were observed as recurrent, that is, all animals 
with a history of allergies had subsequent relapses af-
ter a period of improvement by antimicrobial treatment. 
These animals, in their relapses, presented a high level 
of antimicrobial resistance. 
In our region, there are few studies indicating the 
frequency of antimicrobial resistance of S. pseudonter-
medius. In this sense we can mention the study who 
registered a prevalence of 9.8% (n=207) of S. pseudoin-
termedius methicillin resistant (SPMR) isolated from 
skin infections in dogs in the Province of Buenos Ai-
res 9 .
Likewise, in other study analyzed the antimicrobial 
resistance of 28 isolates of S. pseudintermedius from 
different clinical samples of canines where 10.8% were 
SPMR. Highest levels of resistance were observed for 
erythromycin (39.3%), clindamycin (42.8%), ciproflox-
acin (42.8%) and sulfatrimethoprim (42.8%), which are 
similar to our profiles of susceptibility 29 .
The high percentage of resistance to erythromy-
cin, clindamycin and sulfatrimethoprim observed in 
our study is striking, taking into account that it does 
not coincide with the frequency of the antimicrobial 
treatments implemented. However, it is not ruled out 
whether the animals received previous treatments with 
these antimicrobials.
We must take into account the constitutive MLSB 
phenotype in which an enzyme methylates the 23s 
rRNA, altering the receptor affinities of not only mac-
rolides, but also lincomycins and streptogramins 21 . 
Therefore, we observed roughly the same level of resis-
tance for both erythromycin and clindamycin.
The misuse of these three types of antimicrobials 
is currently evident in clinical practice in our region. 
Also, it should be noticed that most of the animals are 
from specific canine breeds coming from different ca-
nine breeding centers where the indiscriminate use of 
sulfas for “prevention” of coccidia diarrhea is common.
On the other hand, although elevated, this level of 
methicillin-resistance is expected since we had 60% of 
animals with relapses due to allergic causes and espe-
cially since cefalexin was the first antimicrobial choice 
in these dermatopathies.
Antimicrobial Guidelines Working Group of the In-
ternational Society for Companion Animal Infectious 
Diseases 15 recommend clindamycin or lincomisinas, 
first-generation cephalexins, amoxicillin-clavulanic 
acid and sulfa-trimethoprim as a first choice in empiri-
cal treatments for pyodermias. Of second choice, and 
whenever the isolates are susceptible, they recommend 
doxycycline, minocycline, chloramphenicol, fluoroqui-
nolones, rifampicin and aminoglycosides (gentamicin 
and amikacin). 
Finally, as a third option, they recommend linezol-
id, teicoplamine and vancomycin. However, regardless 
of the fact that most (or all) MRSP are susceptible, the 
use of these last three antimicrobials is totally discour-
aged. These drugs should be considered “reserved for 
the treatment of serious infections by methicillin-resis-
tant Staphyloccus aureus in humans” 15 .
In conclusion, it is noteworthy that the results of 
our work showed a high level of resistance to the rec-
ommended as the first option: oxacillin 51% (suscep-
tibility marker for beta-lactams), clindamycin 77%, 
trimethoprim-sulfadiazine 79%. Antimicrobials rec-
ommended as a second option showed intermediate 
susceptibility with 54% for fluoroquinolones, 33% for 
chloramphenicol, 18% for rifampicin, 10% for minocy-
cline and 5% for gentamicin. That is, the high level of 
resistance observed in this study for recommended an-
timicrobials as the first and/or second option generates 
an alert to professionals. These results are mainly due 
to two causes: firstly, the indiscriminate use of antimi-
crobials due to underdiagnosis of the causative agent 
of pyoderma, and secondly, the misuse of the same by 
breeders of purebred dogs.
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